Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
MYK-461 Phase 2 PIONEER-HCM Study to Initiate in Second Half of 2016 Clinical Program Builds on Positive Topline Results from Phase 1 Trials of MYK-461 in HCM MYK-461 Development Program, Product...
-
SOUTH SAN FRANCISCO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
-
MYK-461 Data Suggest Favorable Safety Profile Up to 28 Days Dosing in Healthy Volunteers and Reduction in Excess Cardiac Contractility in All HCM Patients StudiedCompany Plans to Initiate Phase 2...
-
SOUTH SAN FRANCISCO, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
SOUTH SAN FRANCISCO, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
-
- Lead product candidate demonstrates clinical proof of mechanism in hypertrophic cardiomyopathy (HCM) patients; Phase 2 planned for second half of 2016 - Growing evidence in nonclinical studies...